LONDON |
LONDON (Reuters) – GlaxoSmithKline pronounced on Monday it had filed for U.S. capitulation of a new once-weekly diabetes drug albiglutide and would make a identical acquiescence shortly in Europe as it vies for a share of a swarming market.
Albiglutide belongs to a same category of injectable GLP-1 medicines as Victoza, from Novo Nordisk, and Byetta and Bydureon, from Bristol-Myers Squibb and AstraZeneca’s Amylin unit.
The acquiescence by GSK, Britain’s biggest drugmaker, was in line with a devise to find regulatory capitulation for a new product in 2013. As a latecomer to a GLP-1 market, however, analysts trust albiglutide might onslaught to beget vital sales.
Consensus forecasts for albiglutide now indicate to medium annual sales of around $367 million by 2017, according to Thomson Reuters Pharma.
Albiglutide is one of a series of new drugs GSK hopes will revitalise a product portfolio. It is also anticipating for capitulation of a dual lung drugs, Relvar and Anoro; an HIV medicine called dolutegravir; and dual cancer drugs dabrafenib and trametinib.
Further ahead, GSK expects to have pivotal clinical hearing formula on adult to 14 medicines in a subsequent dual years, including dual potentially ground-breaking initial drugs for heart illness and cancer – darapladib and MAGE-A3.
(Reporting by Ben Hirschler)
